AU2017353921B2 - Effective dosing of a child for the treatment of ADHD with methylphenidate - Google Patents

Effective dosing of a child for the treatment of ADHD with methylphenidate Download PDF

Info

Publication number
AU2017353921B2
AU2017353921B2 AU2017353921A AU2017353921A AU2017353921B2 AU 2017353921 B2 AU2017353921 B2 AU 2017353921B2 AU 2017353921 A AU2017353921 A AU 2017353921A AU 2017353921 A AU2017353921 A AU 2017353921A AU 2017353921 B2 AU2017353921 B2 AU 2017353921B2
Authority
AU
Australia
Prior art keywords
methylphenidate
adhd
body weight
hours
released
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017353921A
Other languages
English (en)
Other versions
AU2017353921A1 (en
Inventor
Mark Tengler
Nathan TEUSCHER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neos Therapeutics LP
Original Assignee
Neos Therapeutics LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neos Therapeutics LP filed Critical Neos Therapeutics LP
Publication of AU2017353921A1 publication Critical patent/AU2017353921A1/en
Assigned to NEOS THERAPEUTICS, LP reassignment NEOS THERAPEUTICS, LP Request for Assignment Assignors: NEOS THERAPEUTICS, LP, TENGLER, MARK
Application granted granted Critical
Publication of AU2017353921B2 publication Critical patent/AU2017353921B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • General Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Primary Health Care (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
AU2017353921A 2016-11-01 2017-10-31 Effective dosing of a child for the treatment of ADHD with methylphenidate Active AU2017353921B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662415884P 2016-11-01 2016-11-01
US62/415,884 2016-11-01
PCT/US2017/059256 WO2018085256A1 (en) 2016-11-01 2017-10-31 Effective dosing of a child for the treatment of adhd with methylphenidate

Publications (2)

Publication Number Publication Date
AU2017353921A1 AU2017353921A1 (en) 2019-06-13
AU2017353921B2 true AU2017353921B2 (en) 2023-11-09

Family

ID=62076554

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017353921A Active AU2017353921B2 (en) 2016-11-01 2017-10-31 Effective dosing of a child for the treatment of ADHD with methylphenidate

Country Status (6)

Country Link
US (1) US11166947B2 (enExample)
EP (1) EP3585439A4 (enExample)
JP (1) JP2020504763A (enExample)
KR (2) KR20240033130A (enExample)
AU (1) AU2017353921B2 (enExample)
WO (1) WO2018085256A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021195155A1 (en) * 2020-03-23 2021-09-30 Genentech, Inc. Estimating pharmacokinetic parameters using deep learning
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344215B1 (en) * 2000-10-27 2002-02-05 Eurand America, Inc. Methylphenidate modified release formulations
WO2013003622A1 (en) * 2011-06-28 2013-01-03 Neos Therapeutics, Lp Dosage forms for oral administration and methods of treatment using the same
WO2015188092A1 (en) * 2014-06-06 2015-12-10 Rhodes Pharmaceuticals, L.P. Methods for treating attention deficit hyperactivity disorder with methylphenidate

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060240105A1 (en) 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
CA2348871C (en) * 1998-11-02 2009-04-14 John G. Devane Multiparticulate modified release composition
DK2884961T3 (en) * 2012-08-15 2019-04-23 Tris Pharma Inc METHYLPHENIDATE TABLE WITH EXTENDED RELEASE

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344215B1 (en) * 2000-10-27 2002-02-05 Eurand America, Inc. Methylphenidate modified release formulations
WO2013003622A1 (en) * 2011-06-28 2013-01-03 Neos Therapeutics, Lp Dosage forms for oral administration and methods of treatment using the same
WO2015188092A1 (en) * 2014-06-06 2015-12-10 Rhodes Pharmaceuticals, L.P. Methods for treating attention deficit hyperactivity disorder with methylphenidate

Also Published As

Publication number Publication date
KR20190107655A (ko) 2019-09-20
AU2017353921A1 (en) 2019-06-13
US20190314356A1 (en) 2019-10-17
KR20240033130A (ko) 2024-03-12
WO2018085256A1 (en) 2018-05-11
US11166947B2 (en) 2021-11-09
JP2020504763A (ja) 2020-02-13
EP3585439A4 (en) 2020-07-22
EP3585439A1 (en) 2020-01-01

Similar Documents

Publication Publication Date Title
Swanson et al. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study)
Vocci et al. Approaches to the development of medications for the treatment of methamphetamine dependence
US11207310B2 (en) Use of pridopidine for treating functional decline
Castells et al. Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis
McGough et al. Pharmacokinetics of SLI381 (ADDERALL XR), an extended-release formulation of Adderall
Bredlau et al. Oral ketamine for children with chronic pain: a pilot phase 1 study
Schlienz et al. The effect of high-dose dronabinol (oral THC) maintenance on cannabis self-administration
AU2017315781A1 (en) Use of pridopidine for treating dystonias
KR20120000560A (ko) 아미노피리딘을 사용한 연장 요법을 위한 조성물 및 방법
Wigal et al. A double-blind, placebo-controlled, phase II study to determine the efficacy, safety, tolerability and pharmacokinetics of a controlled release (CR) formulation of mazindol in adults with DSM-5 attention-deficit/hyperactivity disorder (ADHD)
Upadhyaya Substance use disorders in children and adolescents with attention-deficit/hyperactivity disorder: implications for treatment and the role of the primary care physician
AU2017353921B2 (en) Effective dosing of a child for the treatment of ADHD with methylphenidate
CN102143686A (zh) 用4-氨基吡啶持续治疗脱髓鞘病患者
Schenk et al. Serotonin antagonists fail to alter MDMA self-administration in rats
Brams et al. Onset of efficacy of long-acting psychostimulants in pediatric attention-deficit/hyperactivity disorder
JP2020504763A5 (enExample)
US20230120738A1 (en) Methylphenidate compositions for treatment of attention deficit hyperactivity disorder
Katzman et al. Adverse events during dosing of delayed-release/extended-release methylphenidate: learnings from the open-label phase of a registration trial and a real-world postmarketing surveillance program
Bafail Enhancing the Sublingual Permeability of Atropine Sulfate: Effect of pH and Penetration Enhancers
Kurland et al. Contingent Naloxone (./V-allylnoroxymorphone) Treatment of the Paroled Narcotic Addict
Salunke et al. A Two-Sequence, Four-Period, Crossover, Full-Replicate Study to Demonstrate Bioequivalence of Carbamazepine Extended-Release Tablets in Healthy Subjects under Fasting and Fed Conditions.
Karasulu et al. Improving of the accuracy of in vitro-in vivo linear correlation using kinetic models for ultra sustained release theophylline tablets
Childress et al. The use of modified-release methylphenidate in the treatment of attention-deficit/hyperactivity disorder
Morgillo et al. Addiction to Psychoactive Prescription Drugs: Can the Excipients of the Formulations Play a Role?
Starr A new treatment option for attention deficit/hyperactivity disorder

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: NEOS THERAPEUTICS, LP

Free format text: FORMER APPLICANT(S): TENGLER, MARK; NEOS THERAPEUTICS, LP

FGA Letters patent sealed or granted (standard patent)